Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol

Contemporary Clinical Trials(2020)10.1016/j.cct.2020.106009Source: DataRank Database

Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol is a research paper published in Contemporary Clinical Trials (2020). On theSindex it has a DataRank of 0. It has been cited 71 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access71 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Impact (FWCI 4.12)OA: greenTopics (33)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Emma Tallantyre ORCID,Praneeta Raza ORCID,Sarah M. Planchon ORCID,Kunio Nakamura ORCID,Deborah Miller ORCID

Live enrichment

PubMed:32320842 OpenAlex:https://openalex.org/W3016860584

Patient-Centered Outcomes Research Institute

Grant: PCORI/MS-1610-37047

Biogen

National Institutes of Health

Novartis

Merck

National Health Research Institutes

Novartis Pharmaceuticals Corporation

EMD Serono

National Multiple Sclerosis Society

Multiple Sclerosis Society

Roche

FWCI

4.12

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

greenLicense: cc-by-nc-nd

repositoryhttps://orca.cardiff.ac.uk/id/eprint/131100/

publisherhttps://api.elsevier.com/content/article/PII:S1551714420300872?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1551714420300872?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.cct.2020.106009

Fields of Study

Multiple Sclerosis Research StudiesRheumatoid Arthritis Research and TherapiesImmunotherapy and Immune ResponsesHumansMagnetic Resonance ImagingMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingRecurrenceYoung Adult

MeSH Terms

HumansMagnetic Resonance ImagingMultiple SclerosisRecurrenceMultiple Sclerosis, Relapsing-RemittingYoung Adult

Keywords

MedicineMultiple sclerosisMcDonald criteriaObservational studyRandomized controlled trialClinical trialClinical endpointPlaceboGlatiramer acetatePhysical therapyInternal medicineAlternative medicinePsychiatryPathologyDisease Modifying TherapyRelapsing RemittingEarly Highly Effective TreatmentEscalation Approach

Sustainable Development Goals

SDG 0: Good health and well-being